These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 32685741)

  • 1. Detection of somatic
    Yokouchi H; Nishihara H; Harada T; Yamazaki S; Kikuchi H; Oizumi S; Uramoto H; Tanaka F; Harada M; Akie K; Sugaya F; Fujita Y; Takamura K; Kojima T; Higuchi M; Honjo O; Minami Y; Watanabe N; Nishimura M; Suzuki H; Dosaka-Akita H; Isobe H
    Heliyon; 2020 Jul; 6(7):e04439. PubMed ID: 32685741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PIK3CA mutation is a favorable prognostic factor in esophageal cancer: molecular profile by next-generation sequencing using surgically resected formalin-fixed, paraffin-embedded tissue.
    Yokota T; Serizawa M; Hosokawa A; Kusafuka K; Mori K; Sugiyama T; Tsubosa Y; Koh Y
    BMC Cancer; 2018 Aug; 18(1):826. PubMed ID: 30115035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of somatic mutations on prognosis in resected non-small-cell lung cancer: The Japan Molecular Epidemiology for lung cancer study.
    Tamiya A; Koh Y; Isa SI; Kubo A; Ando M; Saka H; Yoshimoto N; Takeo S; Adachi H; Tagawa T; Kawashima O; Yamashita M; Kataoka K; Takenoyama M; Takeuchi Y; Watanabe K; Matsumura A; Kawaguchi T
    Cancer Med; 2020 Apr; 9(7):2343-2351. PubMed ID: 32022477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
    Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
    Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic impact of tumor mutation burden and the mutation in KIAA1211 in small cell lung cancer.
    Zhou M; Fan J; Li Z; Li P; Sun Y; Yang Y; Zhou X; Wang J; Wang Y; Qi H; Cai W; Dai X; Hirsch FR
    Respir Res; 2019 Nov; 20(1):248. PubMed ID: 31699089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
    Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
    Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analysis of the feasibility and prognostic value of circulating tumor DNA in detecting gene mutations in small cell lung cancer].
    Jin Y; Chen YM; Hu X; Tang HR; Yu XM; Fan Y; Xu YJ; Xu HM; Li PS; Li Q; Chang LP; Guan YF; Chen M
    Zhonghua Yi Xue Za Zhi; 2020 Dec; 100(45):3614-3621. PubMed ID: 33333686
    [No Abstract]   [Full Text] [Related]  

  • 8. TP53 and CDKN2A mutations in patients with early-stage lung squamous cell carcinoma: an analysis of the correlations and prognostic outcomes.
    Wang P; Wang F; He H; Chen Y; Lin H; Chen P; Chen X; Liu S
    Ann Transl Med; 2021 Aug; 9(16):1330. PubMed ID: 34532467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical correlation of extensive-stage small-cell lung cancer genomics.
    Dowlati A; Lipka MB; McColl K; Dabir S; Behtaj M; Kresak A; Miron A; Yang M; Sharma N; Fu P; Wildey G
    Ann Oncol; 2016 Apr; 27(4):642-7. PubMed ID: 26802149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive genomic profiling of small cell lung cancer in Chinese patients and the implications for therapeutic potential.
    Hu J; Wang Y; Zhang Y; Yu Y; Chen H; Liu K; Yao M; Wang K; Gu W; Shou T
    Cancer Med; 2019 Aug; 8(9):4338-4347. PubMed ID: 31199602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer.
    Devarakonda S; Rotolo F; Tsao MS; Lanc I; Brambilla E; Masood A; Olaussen KA; Fulton R; Sakashita S; McLeer-Florin A; Ding K; Le Teuff G; Shepherd FA; Pignon JP; Graziano SL; Kratzke R; Soria JC; Seymour L; Govindan R; Michiels S
    J Clin Oncol; 2018 Oct; 36(30):2995-3006. PubMed ID: 30106638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Mutation Profiles with Postoperative Survival in Patients with Non-Small Cell Lung Cancer.
    Goto T; Kunimasa K; Hirotsu Y; Nakagomi T; Yokoyama Y; Higuchi R; Otake S; Oyama T; Amemiya K; Mochizuki H; Omata M
    Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33233456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of OX40
    Yokouchi H; Nishihara H; Harada T; Amano T; Ohkuri T; Yamazaki S; Kikuchi H; Oizumi S; Uramoto H; Tanaka F; Harada M; Akie K; Sugaya F; Fujita Y; Takamura K; Kojima T; Higuchi M; Honjo O; Minami Y; Watanabe N; Nishimura M; Suzuki H; Dosaka-Akita H; Isobe H
    Oncoimmunology; 2021; 10(1):1971430. PubMed ID: 34552823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-region exome sequencing reveals the intratumoral heterogeneity of surgically resected small cell lung cancer.
    Zhou H; Hu Y; Luo R; Zhao Y; Pan H; Ji L; Zhou T; Zhang L; Long H; Fu J; Wen Z; Wang S; Wang X; Lin P; Yang H; Wang J; Song M; Yi X; Yang L; Xia X; Guan Y; Fang W; Yang Y; Hong S; Huang Y; Li P; Zhang Y; Zhou N
    Nat Commun; 2021 Sep; 12(1):5431. PubMed ID: 34521849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma.
    McIntyre CA; Lawrence SA; Richards AL; Chou JF; Wong W; Capanu M; Berger MF; Donoghue MTA; Yu KH; Varghese AM; Kelsen DP; Park W; Balachandran VP; Kingham TP; D'Angelica MI; Drebin JA; Jarnagin WR; Iacobuzio-Donahue CA; Allen PJ; O'Reilly EM
    Cancer; 2020 Sep; 126(17):3939-3949. PubMed ID: 32573775
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Li AJ; Li HG; Tang EJ; Wu W; Chen Y; Jiang HH; Lin MB; Yin L
    World J Gastroenterol; 2018 Feb; 24(5):631-640. PubMed ID: 29434452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
    Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
    JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.
    Ricciuti B; Kravets S; Dahlberg SE; Umeton R; Albayrak A; Subegdjo SJ; Johnson BE; Nishino M; Sholl LM; Awad MM
    J Immunother Cancer; 2019 Mar; 7(1):87. PubMed ID: 30922388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TP53 mutations determined by targeted NGS in breast cancer: a case-control study.
    Andrikopoulou A; Terpos E; Chatzinikolaou S; Apostolidou K; Ntanasis-Stathopoulos I; Gavriatopoulou M; Dimopoulos MA; Zagouri F
    Oncotarget; 2021 Oct; 12(21):2206-2214. PubMed ID: 34676052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing.
    Sun JM; Choi YL; Ji JH; Ahn JS; Kim KM; Han J; Ahn MJ; Park K
    Ann Oncol; 2015 Jan; 26(1):161-166. PubMed ID: 25355724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.